Outcomes included a 6-month PFS rate of 44% for newly diagnosed GBM and 31% for recurrent GBM, with a mOS of 21.0 months and 8.6 months, respectively, supporting the feasibility of MIF inhibition to modulate the immunosuppressive microenvironment [84]. Here, MIF is linked to glioblastoma.